Navigation Links
Data on Higher Dose of Copaxone and Data Showing Copaxone is Most,Cost Effective

results of this study, a large-scale Phase III study designed to confirm the higher efficacy of COPAXONE with the increased dose has been initiated. The study, entitled FORTE (FORTy mg Efficacy of glatiramer acetate), was launched July, 2006, in 137 centers across North America, Europe, Argentina and Israel. Recruitment of approximately 1,000 patients is expected to be completed in May 2007. These dossiers, including these data, are expected to be submitted to the U.S. Food and Drug Administration in 2008.


Phase II Study Design and Results


The study was a randomized, double-blind, parallel-group study conducted at 18 centers in the U.S. in 90 patients with RRMS. The study evaluated the effect of 40 mg of COPAXONE (glatiramer acetate injection) given daily versus 20 mg of COPAXONE on disease activity as measured by MRI and clinical relapses, as well as the safety and tolerability of the 40 mg dose over a period of 9 months. Patients that qualified for this study had clinically-definite MS, had experienced a relapse in the previous year, had at least one Gd-enhancing lesion at screening visit, and had a Kurtzke Expanded Disability Status Scale (EDSS) score of 0-5. Patients were randomized in equal numbers to receive either 40 mg or 20 mg of COPAXONE . All patients underwent an MRI at baseline, and then at months 3, 7, 8 and 9. Neurological examinations were performed at screening, baseline, and again at months 3, 6 and 9, and suspected on-trial relapses were confirmed at an unscheduled visit within 7 days.


COPAXONE 40 mg showed a 38 percent greater reduction of inflammatory disease activity as measured by mean cumulative number of Gd-enhancing T1 MRI lesions versus COPAXONE 20 mg (p=0.0898). The benefit of the 40 mg dose was observed in as soon as 3 months (p=0.005) through MRI measurement. When compared to baseline numbers, the risk of having MRI activity (Gd-enhancement) in the 40 mg group at months 7, 8 and 9 was redu
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)
2. New Clinical Study Results Indicate Higher Early Virologic Response with Celgosivir Combination Therapy in HCV Non-Responders
3. Diabetes Linked to Higher Parkinsons Risk
4. Two New Imaging Studies Show Higher Dose Lipitor Stopped the Progression of Atherosclerosis
5. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
6. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
7. Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients
8. First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
9. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. Data Showing that ReGens Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia
Post Your Comments:
(Date:10/30/2014)... The global market for human vaccines ... of new vaccines. These new products and other ... The Kalorama information report examines the global market ... vaccines for diseases that are already vaccine-preventable. ... communities from diseases spread by person-to-person transmission. The ...
(Date:10/27/2014)... Calif. , Oct. 27, 2014  RenovoRx, a ... blood flow and delivery of fluids to selected sites ... Board of Directors has appointed Shaun Bagai ... of the RenovoRx Board of Directors. Bagai brings more ... industry. Bagai joined RenovoRx in June 2014 ...
(Date:10/27/2014)... 27, 2014  In the last few weeks, Ebola has gone ... to a worldwide crisis when a traveler to ... died, and two nurses were infected. While much of ... use of modern technology, such as electronic health records (EHRs), to ... This week, InformationWeek Healthcare Editor Alison Diana fills in ...
Breaking Medicine Technology:Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 2Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 3RenovoRx Board Names Shaun R. Bagai as CEO 2EHRs in the Age of Ebola: Discuss on InformationWeek 2EHRs in the Age of Ebola: Discuss on InformationWeek 3
... 2012 /PRNewswire-Asia/ -- China Kanghui Holdings (NYSE: ... leading domestic developer, manufacturer and marketer of orthopedic ... operating subsidiaries, Beijing Libeier Biology Engineering Research Institute ... Ltd, have received approvals from relevant PRC authorities ...
... MAPLE GROVE, Minn., Jan. 11, 2012  Snow tires? Check! ... Just like a car, you need to prepare your ... extreme temperature changes can result in skin that is ... brakes on severe dry skin before it starts with ...
Cached Medicine Technology:China Kanghui Holdings Renews High and New Technology Enterprises Status of Its PRC Operating Subsidiaries 2Don't Let Your Skin Take a Backseat As You Prepare for Winter 2Don't Let Your Skin Take a Backseat As You Prepare for Winter 3
(Date:10/30/2014)... Home Care Assistance – Halton/Peel Region ( ... senior care, is weighing in on a recent study ... study, performed by the University of Illinois, analyzed 88 ... a week-long period and observed how much time was ... examining the structural soundness of the white matter in ...
(Date:10/30/2014)... FL (PRWEB) October 30, 2014 ... Joint Commission Accredited teleradiology and specialty telemedicine solutions ... in addition to its existing teleradiology services at ... second opinion and expert telemedicine services, to the ... , As a result of this innovative partnership, ...
(Date:10/30/2014)... 2014 Victory Healthcare, a privately ... third quarter infection rates and patient satisfaction scores. ... of only two percent or less, and the ... 98 percent. , “We are delighted with our ... satisfaction scores,” said Robert Helms, chairman and CEO ...
(Date:10/30/2014)... HealthDay Reporter WEDNESDAY, Oct. ... chemical during pregnancy may have effects on genital development in ... baby boys born to moms with greater exposure to a ... -- the space between the genitals and anus. Anogenital distance ... of exposure to androgens ("male" hormones) during pregnancy. The ...
(Date:10/30/2014)... WEDNESDAY, Oct. 29, 2014 (HealthDay News) -- Americans, opinions ... political lines, a new study finds. Democratic voters ... (ACA), according to the researchers. Almost three-quarters of Democrats ... ACA. Thirty percent want Congress to implement the current ... of the ACA. Among Independent voters, one-third want ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:Voters' Views on Obamacare Split Along Party Lines 2
... in the retina that is responsible for maintaining the health ... in a living retina for the first time. , The ... identify the onset of many diseases of the eye long ... issue of Investigative Ophthalmology and Visual Science ., "Our ...
... Tired of Putting Money in the Hands of Beauty Corporations ... / or Counseling to Remain Youthful? Now one does ... Never Before Published Secrets to Eternal Youth and Immortality, gives ... so that folks can attain and maintain the Age they ...
... Jade Goody who will be left behind without a ... Chantel "Chani" Christie who recently won the 2009 Martin ... is set to donate proceeds from her debut album ... star, Jade Goody. In addition, she also plans to ...
... facility already ahead of scheduleMARLTON, N.J., Feb. 25 ... exempt bonds from the New Jersey Health Care Facilities ... The bonds will be used to continue the financing ... our plan for finance in place and have met ...
... continued positive cash flow from operationsBOSTON, Feb. 25 ... a leader in radiology and medical image and ... for the fourth quarter and year ended December ... Financial Highlights Revenue : Total revenue for ...
... Feb. 25 Mesa Laboratories, Inc. (Nasdaq: ... manufacturing quality control applications, today announced the appointment of ... extensive experience to Mesa from his role as Chief ... Inc., a registered investment adviser based in New York ...
Cached Medicine News:Health News:'Dark cells' of living retina imaged for the first time 2Health News:'Dark cells' of living retina imaged for the first time 3Health News:What the Billion Dollar Beauty Industry Does Not Want Leaked: That One Can Actually Reverse Aging for Free by Moving Only to the Right. We Smell a Nobel. 2Health News:Chantel 'Chani' Christie Will Donate Proceeds From Her Top-Selling Debut Album 'My Dream' to the Children of Terminally Ill TV Star Jade Goody 2Health News:Virtua Health Takes Next Step for Continuing Hospital Construction 2Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 2Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 3Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 4Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 5Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 6Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 7Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 8Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 9Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 10Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 11Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 12Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 13Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 14Health News:Mesa Labs Announces Appointment of New Director 2
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Cottle Tenaculum Skin Hook. 5 1/2" small, shallow curve....
Goldman single hook....
Needle tip electrode, davol advantage electrosurgical attachments, 33cm (with extendible outer sheath), non-sterile. These products are supplied non-sterile and must be sterilized before use. Reusabl...
Medicine Products: